Trial Profile

Study to Evaluate the Effect of Different Pre-seasonal BM32 Dosing Schedules on the Rapid Induction of a Protective IgG Immune Response

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Grass pollen allergy immunotherapy (Primary)
Indications Hypersensitivity
Focus Pharmacodynamics
Sponsors Biomay

Most Recent Events

05 Mar 2018 Results (n=124) assessing clinical efficacy of a recombinant grass pollen vaccine one year after a 4 month treatment course, were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
26 Jan 2017 Results published in the Biomay media release.
26 Jan 2017 Primary endpoint (Titer of allergen specific IgG4 antibodies) has been met, according to Biomay media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com